Search research articles
Contact Us
Filters
Showing results (1-10 of 92) with videos related to
Page
of 10
Sort By:
Journal of Biopharmaceutical Statistics
|
November 9, 2010
Editorial: Adaptive designs: appealing in development of therapeutics, and where do controversies lie?
Sue-Jane Wang
Journal of the Formosan Medical Association = Taiwan Yi Zhi
|
January 9, 2009
Utility of adaptive strategy and adaptive design for biomarker-facilitated patient selection in pharmacogenomic or pharmacogenetic clinical development program
Sue-Jane Wang
Pharmaceutical Statistics
|
October 25, 2007
Biomarker as a classifier in pharmacogenomics clinical trials: a tribute to 30th anniversary of PSI
Sue-Jane Wang
Pharmaceutical Statistics
|
September 8, 2010
Multi-regional clinical trials--what are the challenges?
Sue-Jane Wang
Contemporary Clinical Trials
|
August 10, 2020
Recent advances in clinical trial design considerations in Thera"nostics"
Sue-Jane Wang
Journal of Biopharmaceutical Statistics
|
November 21, 2007
Discussion of the "White Paper of the PhRMA Working Group on adaptive dose-ranging designs"
Sue-Jane Wang
Journal of Biopharmaceutical Statistics
|
November 9, 2010
Perspectives on the use of adaptive designs in clinical trials. Part I. Statistical considerations and issues
Sue-Jane Wang
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 10, 2013
Modified toxicity probability interval design: a safer and more reliable method than the 3 + 3 design for practical phase I trials
Yuan Ji, Sue-Jane Wang
Journal of Biopharmaceutical Statistics
|
January 8, 2014
Standardization for subgroup analysis in randomized controlled trials
Ravi Varadhan, Sue-Jane Wang
Contemporary Clinical Trials
|
January 2, 2021
Guest editors-in-chief note to COVID-19 special issue
Zheng Su, Sue-Jane Wang
Page
of 10
Search research articles
Search
Showing results (1-10 of 92) with videos related to
Sort By:
Page
of 10
Journal of Biopharmaceutical Statistics
|
November 9, 2010
Editorial: Adaptive designs: appealing in development of therapeutics, and where do controversies lie?
Sue-Jane Wang
Journal of the Formosan Medical Association = Taiwan Yi Zhi
|
January 9, 2009
Utility of adaptive strategy and adaptive design for biomarker-facilitated patient selection in pharmacogenomic or pharmacogenetic clinical development program
Sue-Jane Wang
Pharmaceutical Statistics
|
October 25, 2007
Biomarker as a classifier in pharmacogenomics clinical trials: a tribute to 30th anniversary of PSI
Sue-Jane Wang
Pharmaceutical Statistics
|
September 8, 2010
Multi-regional clinical trials--what are the challenges?
Sue-Jane Wang
Contemporary Clinical Trials
|
August 10, 2020
Recent advances in clinical trial design considerations in Thera"nostics"
Sue-Jane Wang
Journal of Biopharmaceutical Statistics
|
November 21, 2007
Discussion of the "White Paper of the PhRMA Working Group on adaptive dose-ranging designs"
Sue-Jane Wang
Journal of Biopharmaceutical Statistics
|
November 9, 2010
Perspectives on the use of adaptive designs in clinical trials. Part I. Statistical considerations and issues
Sue-Jane Wang
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 10, 2013
Modified toxicity probability interval design: a safer and more reliable method than the 3 + 3 design for practical phase I trials
Yuan Ji, Sue-Jane Wang
Journal of Biopharmaceutical Statistics
|
January 8, 2014
Standardization for subgroup analysis in randomized controlled trials
Ravi Varadhan, Sue-Jane Wang
Contemporary Clinical Trials
|
January 2, 2021
Guest editors-in-chief note to COVID-19 special issue
Zheng Su, Sue-Jane Wang
Page
of 10